1 active not recruiting, 1 completed, 1 terminated. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow caficrestat: new trials by email Literature Review of caficrestat trials Research Report on caficrestat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA) NACA - Hereditary Cystatin C Amyloid Angiopathy (HCCAA), Hemorrhage Brain | Phase 2 | Active not recruiting | Arctic Therapeutics | 15 | 2024-04-03 | 2026-07-21 |
| Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer Eribulin Mesylate, Grapiprant - Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2021-12-21 | 2025-06-13 |
| Cardiovascular Effects of COVID-19 AT-001 - COVID-19 | Phase 2 | Completed | NYU Langone Health | 81 | 2020-04-08 | 2021-09-16 |
COVID-19 (1) · Cerebral Amyloid Angiopathy, Familial (1) · Cerebral Hemorrhage (1) · Dementia (1) · Inflammatory Breast Neoplasms (1) · Intracranial Hemorrhages (1)
Arctic Therapeutics (1) · M.D. Anderson Cancer Center (1) · NYU Langone Health (1)
United States (2) · Iceland (1)
Sadia Saleem (1) · Stuart Katz, MD (1)
2023 (1)